We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies

Maz5.0

Mazdutide Research

Mostly mechanism / observational

18 peer-reviewed studies

What the evidence says

Mostly mechanism / observational

Most Mazdutide studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.

Most evidence is from high-quality meta-analyses and randomised trials published 2021–2026 with a typical study size of 349 participants.

Based on 18 studies · 3 meta-analyses · 11 RCTs · 3,917 total participants

Confidence

High confidence

By outcome

Weight managementPhase-3 trials showed ~11-14% weight loss at 48 weeks and ~16.7% at 60 weeks (9 mg) versus placebo in Chinese adults · Months (dose-escalated)
Mostly mechanism / observational15 studies
Glycemic & metabolic controlLowered HbA1c by up to ~2.2% vs placebo (phase-3 monotherapy); superior to dulaglutide head-to-head · Weeks to months
Mostly mechanism / observational11 studies
Safety profile
Mostly mechanism / observational5 studies
Heart & blood pressure
Too few graded studies1 study
Liver fat & MASLD
Too few graded studies1 study

Active research area

18 studies in the last 5 years · Latest meta-analysis: 2026

20212026

1Meta-Analysis2024

Nalisa DL, Cuboia N, Dyab E, Jackson IL, Felix HJ, Shoki P · Front Endocrinol (Lausanne) (2024)

No plain-language summary recorded for this citation — open the paper to read its abstract.

View source Free full text

2Meta-Analysis2026

Azam MH, Azam MH, Azam KU, Azam MA, Afridi MK, Waqas SA · Diabetes Obes Metab (2026)

No plain-language summary recorded for this citation — open the paper to read its abstract.

View source

3RCTn=461 · medium study2026

In plain English: At week 60, the mean percentage change in body weight from baseline was -16.65%... in the mazdutide group compared with -1.50%... in the placebo group.

Gao L, Jiang H, Cai H, Tian J, Shi B, Qiu W, Huang C, et al. · JAMA (2026)

60-week phase-3 double-blind placebo-controlled RCT (GLORY-2) in 461 Chinese adults with obesity (BMI >=30), mazdutide 9 mg vs placebo
Mean weight change -16.65% vs -1.50% placebo (between-group difference -15.15%); 84.3% lost >=5% vs 33.1%
GI adverse events common at 9 mg: vomiting 53.1%, nausea 46.9%, diarrhea 39.4% (most mild-to-moderate)

View source Free full text

4RCT2026

Ji L, Jiang H, Cheng Z, Li X, Pang S, Zhang Y · Med (2026)

No plain-language summary recorded for this citation — open the paper to read its abstract.

View source

5RCT2022

Jiang H, Pang S, Zhang Y, Yu T, Liu M, Deng H · Nat Commun (2022)

No plain-language summary recorded for this citation — open the paper to read its abstract.

View source Free full text

6RCT2023

Ji L, Jiang H, Cheng Z, Qiu W, Liao L, Zhang Y · Nat Commun (2023)

No plain-language summary recorded for this citation — open the paper to read its abstract.

View source Free full text

7RCT2025

Ji L, Jiang H, Bi Y, Li H, Tian J, Liu D · N Engl J Med (2025)

No plain-language summary recorded for this citation — open the paper to read its abstract.

View source

8RCT2024

Zhang B, Cheng Z, Chen J, Zhang X, Liu D, Jiang H · Diabetes Care (2024)

No plain-language summary recorded for this citation — open the paper to read its abstract.

View source Free full text

9RCT2026

Zhu D, Zhao J, Cai H, Chu X, Xiu S, Song C · Nature (2026)

No plain-language summary recorded for this citation — open the paper to read its abstract.

View source

10Meta-Analysis2024

Ayesh H, Ayesh S, Niswender K. · American journal of therapeutics (2024)

Published in American journal of therapeutics (2024)

View source

11Reviewn=2,292 · very large study2026

In plain English: Longer-term, multi-ethnic studies are needed to confirm durability, generalizability, and cardiovascular safety.

Kamrul-Hasan ABM, Chatterjee S, Ashraf H, Nagendra L, Khalil I, Hasan M, Ahsan A, Dutta D. · Diabetes, obesity & metabolism (2026)

Co-primary outcomes were percent change in body weight and change in HbA1c.
Random-effects models were used to generate pooled mean differences (MDs) or risk ratios with 95% confidence intervals, and the certainty of the evidence (COE) was assessed using GRADE.
In overweight/obesity without diabetes, mazdutide 3, 4, and 6 mg reduced body weight more than placebo (MDs -6.56%, -9.92%, and -11.1%, respectively; very low COE due to substantial heterogeneity and few trials).

View source

12RCTn=731 · large study2026

In plain English: Both doses of mazdutide showed non-inferiority and superiority to the 1.5-mg dose of dulaglutide in terms of the mean change in... HbA1c... and significantly greater reductions in body weight.

Guo L, Zhang B, Xue X, Zhang X, Cai H, Jiang H, Zhang L, et al. · Nature (2026)

Phase-3 head-to-head RCT in 731 Chinese adults with type 2 diabetes on background oral agents, mazdutide 4/6 mg vs dulaglutide 1.5 mg for 28 weeks
HbA1c treatment difference vs dulaglutide -0.24% (4 mg) and -0.30% (6 mg) — non-inferior and superior
Greater weight loss vs dulaglutide: difference -3.78% (4 mg) and -5.76% (6 mg)

View source

13Review2026

In plain English: Cardiovascular effects of GCGR signaling by dual agonists should be clarified per compound by ongoing clinical trials, notably the cardiovascular outcomes trial SYNCHRONIZE-CVOT (A Study to Test the Effect of Survodutide [BI 456906] on Cardiovascular Safety in People With Overweight or Obesity) and thorough corrected QT study of survodutide.

Kushner PR, Michos ED. · Journal of the American Heart Association (2026)

Mazdutide and survodutide also reduced blood pressure and hyperglycemia.
However, at least 1 other dual agonist was discontinued, partly due to unacceptably large increases in heart rate and prolongation of the corrected QT interval.
These between-compound differences may reflect different potencies for activating the GCGR and GLP-1 receptors.

View source

14n=349 · medium study2026

In plain English: Conclusion DERAMS-3 is the first head-to-head trial to compare the efficacy and safety of mazdutide versus semaglutide in Chinese adults with T2D and obesity, with an expected completion date in early 2026.

Luo Y, Jiang H, Shi B, Cai H, Wang H, Li S, Qiu W, Li Y, Zhou R, Deng H, Guo Q, Li L, Pei L, Zhang HH, Qian L, Ji L. · Contemporary clinical trials (2026)

The primary endpoint is the proportion of participants achieving glycated hemoglobin <7.0 % and weight reduction of ≥10 % at week 32.
Results A total of 349 participants were enrolled and randomized, the overall mean age was 42.4 years, 44.7 % of participants were male.
The mean baseline duration of T2D was 1.8 years, and 39.5 % of participants were on metformin.

View source

15RCTn=24 · very small study2025

Bhattachar SN, Tham LS, Li Y, Chua L, Ng SX, Tang Y, Ibriga H, Ni W, Gurbuz S, Mather KJ, Thomas MK. · Diabetes, obesity & metabolism (2025)

Aim Mazdutide, an agonist of glucagon-like peptide-1 and glucagon receptors, significantly reduced weight in early phase trials at doses up to 10 mg.
Results At Week 20, mean percent change from baseline in body weight was -20.0% (SE: 1.9) for Cohort 1 and -21.0% (1.2) for Cohort 2 versus -0.1% (1.5) for placebo (p < 0.001).
Weight loss of ≥15% was achieved by 66.7% of Cohort 1 and 75.0% of Cohort 2.

View source

16RCTn=24 · very small study2022

In plain English: The mean percent change from baseline to week 12 in body weight were -11.7%... for participants receiving mazdutide in the 9 mg cohort and -1.8%... for participants receiving placebo.

Ji L, Gao L, Jiang H, Yang J, Yu L, Wen J, et al. · EClinicalMedicine (2022)

Phase-1b multiple-ascending-dose RCT in 24 Chinese adults with overweight/obesity, high-dose mazdutide (9 mg, 10 mg cohorts) vs placebo
12-week weight change -11.7% (9 mg) vs -1.8% placebo (ETD -9.8%); 16-week -9.5% (10 mg) vs -3.3% placebo
No serious adverse events; all treatment-emergent events mild or moderate (URTI, diarrhea, decreased appetite, nausea)

View source Free full text

17Review2025

In plain English: In June 2025, mazdutide received its first approval, in China, for use... in long-term body weight management in adults... Subsequently, in September 2025, mazdutide also received approval in China for use in glycaemic control in adults with T2D.

Shirley M. · Drugs (2025)

Regulatory/development review of mazdutide, a dual glucagon (GcgR) and GLP-1 receptor agonist co-developed by Innovent Biologics and Eli Lilly
First approval in China (June 2025) for long-term weight management; second China approval (September 2025) for type 2 diabetes
Not FDA- or EMA-approved; investigational outside China

View source

18RCTn=36 · small study2021

In plain English: Estimated percent changes in mean body weight from baseline to week 12 were -4.81%... -6.40%... and -6.05%... for participants receiving IBI362 in the 3.0 mg, 4.5 mg and 6.0 mg cohort... compared with 0.60%... for those receiving placebo.

Ji L, Jiang H, An P, Deng H, Liu M, Li L, et al. · EClinicalMedicine (2021)

First-in-Chinese phase-1b multiple-ascending-dose RCT in 36 adults with overweight/obesity, IBI362 3/4.5/6 mg vs placebo over 12 weeks
Dose weight loss -4.81% to -6.40% vs +0.60% placebo; no discontinuations for safety, no serious adverse events
GI events and decreased appetite most common, mostly mild; three participants had mild asymptomatic ECG cardiac findings

View source Free full text

View in Research Library

Mazdutide Research

Mostly mechanism / observational

Efficacy and safety of Mazdutide on weight loss among diabetic and non-diabetic patients: a systematic review and meta-analysis of randomized controlled trials.

Efficacy and Safety of Mazdutide in Managing Overweight and Obesity Among Non-Diabetic Adults: A Meta-Analysis of Randomised Controlled Trials.

Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial.

Mazdutide 9 mg in Chinese adults with a body mass index ≥30 kg/m2 but without diabetes: A phase 2 randomized controlled trial.

A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes.

A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity.

Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight.

Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.

Mazdutide versus placebo in Chinese adults with type 2 diabetes.

Mazdutide Versus Dulaglutide for Weight Loss and Diabetes Management: Meta-Analysis of Randomized Clinical Trials

Efficacy and Safety of the Dual Glucagon-Like Peptide-1 and Glucagon Receptor Agonist Mazdutide in Predominantly Chinese Adults With Obesity and/or Type 2 Diabetes: A Systematic Review and Meta-Analysis

Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes.

Cardiovascular Effects of Glucagon Receptor Signaling Alone and Combined With Glucagon-Like Peptide-1 Receptor Signaling in Multiagonists: A Narrative Review With a Translational Focus

Mazdutide versus Semaglutide for the treatment of type 2 diabetes and obesity: Rationale, design and baseline data of DREAMS-3 phase 3 trial

Mazdutide reduces body weight in adults with overweight or obesity: A high-dose Phase 1 trial

Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial.

Mazdutide: First Approval.

IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study.